middle.news
How Did Chimeric Therapeutics Navigate ASX Scrutiny Over AML Trial Data Timing?
11:02am on Thursday 6th of November, 2025 AEDT
•
Healthcare
Read Story
How Did Chimeric Therapeutics Navigate ASX Scrutiny Over AML Trial Data Timing?
11:02am on Thursday 6th of November, 2025 AEDT
Key Points
No dose-limiting toxicities or severe adverse events reported in dose escalation phase
CORE-NK cells showed persistence in patients’ blood beyond two weeks
Two new complete responses in frontline AML patients confirmed post-conference
Company verified data with MD Anderson Cancer Center before ASX announcement
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Chimeric Therapeutics (ASX:CHM)
OPEN ARTICLE